BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F, Dehghan-Manshadi SA, Kazemnejad S. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Res Ther 2022;13:96. [PMID: 35255966 DOI: 10.1186/s13287-022-02771-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kirkham AM, Bailey AJ, Shorr R, Lalu MM, Fergusson DA, Allan DS. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.10.003] [Reference Citation Analysis]
2 Chaudhary JK, Saini D, Chaudhary PK, Maurya A, Verma GK, Gupta AK, Roshan R, Vats TK, Garg N, Yadav D, Kant N, Meena AK, Mirza-shariff AA. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19. Cells 2022;11:2175. [DOI: 10.3390/cells11142175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]